Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

Withdrawn before enrolling · Not applicable · Has a placebo group

Conditions studied: Postdural Puncture Headache

In brief

This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED). Half of the patients will receive a true nerve block with lidocaine and bupivacaine. The other half will receive a placebo nerve block.

Key facts

Study ID

NCT02517931

Run by

University of Arkansas

People needed

0

Starts

2019-01-01

Expected to finish

2019-09-23

Last updated by the study team

2019-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Active postdural puncture headache within 7 days after diagnostic lumbar puncture
• Age ≥ 18 years.
• American Society of Anesthesiologists (ASA) physical status ≤ 3

You may not qualify if…

• Known coagulopathy
• Known nasal septal deviation or abnormalities
• Medical conditions contraindicated to lidocaine or bupivacaine

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.